Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
A court has found that United Therapeutics' interference with the launch of a generic Treprostinil injection caused losses of more than $137 million to Liquidia Technologies. This ruling serves as a warning to United Therapeutics once Liquidia's Yutrepia comes to market.
Court Finds $UTHR Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million. $LQDA https://t.co/dSld3WTTPB
No $ gain for $LQDA but a good hit against $UTHR and warning to them once Yutrepia comes to market. https://t.co/X1z3D1LVwR
$LQDA Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million https://t.co/rGkMWXCRnE
